JO
EIGR

John Overdeck’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

John Overdeck’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-597
Closed -$5.46K – 3444
2023
Q3 		$5.46K Sell
597
-810
-58% -$16.3K ﹤0.01% 2913
2023
Q2 		$29.7K Sell
1,407
-793
-36% -$24.4K ﹤0.01% 2879
2023
Q1 		$59.2K Sell
2,200
-7,411
-77% -$345K ﹤0.01% 2728
2022
Q4 		$340K Buy
9,611
+7,924
+470% +$952K ﹤0.01% 2196
2022
Q3 		$381K Sell
1,687
-378
-18% -$92.9K ﹤0.01% 1895
2022
Q2 		$390K Buy
2,065
+1,162
+129% +$234K ﹤0.01% 1914
2022
Q1 		$225K Buy
+903
New +$143K ﹤0.01% 2308
2021
Q4 		– Sell
-901
Closed -$181K – 5040
2021
Q3 		$181K Sell
901
-233
-21% -$55.4K ﹤0.01% 3987
2021
Q2 		$290K Sell
1,134
-4,805
-81% -$1.2M ﹤0.01% 3540
2021
Q1 		$1.58M Sell
5,939
-2,162
-27% -$681K ﹤0.01% 1892
2020
Q4 		$2.99M Sell
8,101
-1,215
-13% -$349K 0.01% 1239
2020
Q3 		$2.27M Buy
9,316
+1,899
+26% +$591K 0.01% 1215
2020
Q2 		$2.14M Buy
7,417
+367
+5% +$108K 0.01% 1063
2020
Q1 		$1.44M Buy
7,050
+3,735
+113% +$1.19M 0.01% 1170
2019
Q4 		$1.48M Buy
3,315
+2,478
+296% +$879K ﹤0.01% 1837
2019
Q3 		$257K Sell
837
-1,744
-68% -$567K ﹤0.01% 3050
2019
Q2 		$821K Sell
2,581
-96
-4% -$33.2K ﹤0.01% 2104
2019
Q1 		$1.12M Buy
2,677
+1,322
+98% +$531K ﹤0.01% 1752
2018
Q4 		$413K Buy
1,355
+524
+63% +$169K ﹤0.01% 2234
2018
Q3 		$299K Buy
831
+44
+6% +$15.1K ﹤0.01% 2778
2018
Q2 		$288K Buy
+787
New +$280K ﹤0.01% 2963
2016
Q1 		– Sell
-188
Closed -$125K – 3197
2015
Q4 		$125K Buy
188
+51
+37% +$28.9K ﹤0.01% 2548
2015
Q3 		$65K Sell
137
-243
-64% -$129K ﹤0.01% 2093
2015
Q2 		$215K Buy
380
+218
+135% +$603K ﹤0.01% 2591
2015
Q1 		$1.38M Buy
162
+112
+224% +$979K 0.01% 1379
2014
Q4 		$442K Buy
+50
New +$290K ﹤0.01% 1782

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.41B AUM 39.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

John Overdeck's EIGR Position: Q4 2023 in Review

John Overdeck sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2023, closing a stake of 597 shares — an estimated $5.46K sold.

John Overdeck first reported a position in EIGR in Q4 2014 and held it in 26 quarters. The position peaked at $2.99M in Q4 2020. 43 funds tracked by Wall St. Rank hold EIGR as of Q4 2023.

  • John Overdeck reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
  • John Overdeck sold 597 Eiger BioPharmaceuticals, Inc. shares in Q4 2023, an estimated $5.46K.
  • John Overdeck first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 26 quarters.
  • John Overdeck's Eiger BioPharmaceuticals, Inc. position peaked at $2.99M in Q4 2020.
  • 43 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2023.

Based on Two Sigma Investments's 13F filing for Q4 2023, filed 14 Feb 2024.